此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

用于患有囊性纤维化的青春期和年轻成年女性的雌激素贴剂 (STURDY)

2026年11月11日 更新者:Johns Hopkins University

用于患有 CF 的青春期和年轻成年女性的透皮雌二醇

The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF). The study has two main components, an observational study and a feasibility sub-study. The main questions it aims to answer are:

  • How do different forms of hormonal contraception (e.g. birth control pill or other progesterone only methods) impact bone health?
  • Is a study of transdermal estradiol (estrogen skin patches) feasible in this group?
  • How does transdermal estradiol impact bone health and quality of life?

Participants in the observational study will have three study visits (baseline, 6 months, and 12 months). At all visits, participants will have blood drawn and will complete questionnaires. At the baseline and 12 month visits, participants will additionally have x-rays and DXAs (bone density assessment). Between visits, participants will complete brief questionnaires. Researchers will compare various measurements over time to assess the impact of different forms of hormonal contraception.

Participants in the feasibility sub-study will apply transdermal estradiol patches once weekly for 12 months, fill out brief quality-of-life surveys in between study visits, and complete blood draws and questionnaires at four study visits (baseline, 3 months, 6 months, and 12 months). The participants will also have x-rays and DXAs performed at the baseline and 12 month visits. Researchers will examine changes in various measurements to determine the impact of transdermal estradiol.

研究概览

研究类型

介入性

注册 (估计的)

75

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Cynthia Wang
  • 电话号码:410-929-3056
  • 邮箱:cwang202@jh.edu

学习地点

    • Maryland
      • Baltimore、Maryland、美国、21287
        • 招聘中
        • Johns Hopkins
        • 首席研究员:
          • Malinda Wu, MD, MSc
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1秒 至 100年 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Observational Study:

Inclusion Criteria:

  • CF Diagnosis
  • Females who have had at least 1 menstrual cycle
  • Planning to use same formulation of estrogen supplementation (or none) for duration of study

Exclusion Criteria:

  • Use of anti-osteoporosis therapy including anti-resorptives such as bisphosphonates or anabolic agents such as teriparatide or denosumab
  • Conditions in which bone loss is known to be present or expected to occur, such as lactation
  • Pregnant or planning to become pregnant
  • In the opinion of the CF care team or study investigators participant should not participate in the study
  • Inability to provide informed consent/assent

Feasibility Sub-Study:

Inclusion Criteria:

  • All of above and
  • <35 years old
  • At least 2 years after first menstrual cycle
  • Symptoms of low estrogen and/or low serum estradiol levels (< 50 pg/mL)

Exclusion Criteria:

  • All of above and
  • Contraindications to transdermal estradiol
  • Current use of systemic estrogen (such as estrogen-containing oral contraceptive pill)
  • Previous lung or liver transplant
  • Use of chronic systemic glucocorticoids
  • Severe vitamin D deficiency (serum 25(OH)D < 6 ng/mL)
  • Conditions increasing risk of clot: history of previous deep vein thrombus or pulmonary embolism, current immobility, current peripherally inserted central catheter or mediport, known hypercoagulable condition
  • Baseline study visit falls between 1 and 8 weeks after initiation of CF transmembrane receptor (CFTR) modulator
  • Currently in pulmonary exacerbation
  • Recent antibiotic use within the past 4 weeks for an acute pulmonary exacerbation
  • Unwilling or unable to use a non-estrogen containing method of contraception such as barrier, abstinence, or progesterone-only method

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Observational Study

Participants will complete three study visits (baseline, 6 months, and 12 months) involving DXAs (bone density assessment), x-rays, blood draws, and questionnaires.

实验性的:Transdermal Estradiol/Cyclic Progesterone

Participants will apply transdermal estradiol patches (0.1 mg/day) weekly for 12 months following baseline study visits. Participants not already using a progesterone-containing contraceptive will also take progesterone (200 mg) for 10 days per month.

Transdermal estradiol 0.1 mg/day, applied once weekly

其他名称:
  • 克里马拉
  • 透皮雌二醇

Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive

其他名称:
  • 钷

研究衡量的是什么?

主要结果指标

结果测量
大体时间
双能 X 射线吸收测定法 (DXA) 评估的腰椎骨密度变化
大体时间:基线和 12 个月
基线和 12 个月

次要结果测量

结果测量
措施说明
大体时间
Change in serum procollagen type I intact N-terminal propeptide (P1NP) levels (mcg/L)
大体时间:Baseline and 12 months

P1NP is a marker of bone turnover.

Baseline and 12 months
Change in serum C-terminal telopeptide of type I collagen (CTX-1) levels (pg/mL)
大体时间:Baseline and 12 months

CTX-1 is a marker of bone turnover.

Baseline and 12 months
Change in quality of life as assessed by Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) questionnaire
大体时间:Baseline and 12 months

CFRSD-CRISS is a brief survey to assess quality of life of people with cystic fibrosis that will be taken by participants twice per month. The questionnaire is scored from 0-100 with higher scores indicating increased symptom severity.

Baseline and 12 months

其他结果措施

结果测量
措施说明
大体时间
Study procedure completion rate
大体时间:Evaluated at completion of study, approximately two years

Percentage of participants enrolled in study who complete all study procedures.

Evaluated at completion of study, approximately two years
Acceptability as determined by participant report
大体时间:Across 12 months of study participation per participant

Acceptability during study participation by 5 point Likert scale, with a score or 3 or greater considered acceptable.

Across 12 months of study participation per participant

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Malinda Wu, MD, MSc、Johns Hopkins University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年5月2日

初级完成 (估计的)

2028年1月1日

研究完成 (估计的)

2029年1月1日

研究注册日期

首次提交

2023年1月10日

首先提交符合 QC 标准的

2023年1月19日

首次发布 (实际的)

2023年1月30日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅